Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator; The Canadian Implantable Defibrillator Study

Circulation

Volumn 104, Issue 14, 2001, Pages 1622-1626

  Sheldon, Robert ^a   O'Brien, Bernie J ^b   Blackhouse, Gordon ^b   Goeree, Ron ^b   Mitchell, Brent ^a   Klein, George ^c   Roberts, Robin S ^b   Gent, Michael ^b   Connolly, Stuart J ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Cardioversion; Cost benefit analysis; Defibrillation; Trials

Indexed keywords

AMIODARONE;

ADULT; AGE; AGED; ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANT; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SURVIVAL RATE;

EID: 0035797854     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc3901.096720     Document Type: Article

References (28)

1. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal in ventricular arrhythmias
2. Canadian Implantable Defibrillator Study (CIDS): A randomized trial of the implantable cardioverter against amiodarone
3. Randomized comparison of anti-arrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The cardiac arrest study Hamburg (CASH)
4. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials
5. Cost-effectiveness of the implantable cardioverter-defibrillator: Results from the Canadian Implantable Defibrillator Study (CIDS)
6. Identification of patients most likely to benefit from ICD therapy: The Canadian Implantable Defibrillator Study
7. Nonparametric estimation from incomplete observations
8. Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation
9. Bootstrap methods: Another look at the jackknife
10. Estimating medical costs from incomplete follow-up data
11. Definition, interpretation and calculation of cost-effectiveness acceptability curves
12. How attractive does a new technology have to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations
13. Cost-effectiveness in heart disease, III: Ischemia, congestive heart failure, and arrhythmias
14. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death
15. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia
16. Implantable cardioverter-defibrillator therapy: The sickest patients benefit the most
17. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias: AVID Investigators: Antiarrhythmics versus implantable defibrillators
18. Do baseline characteristics accurately discriminate between patients likely versus unlikely to benefit from implantable defibrillator therapy?
19. Screening for hypertension
20. Cost-effectiveness analysis of transplantation
21. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary artery disease
22. The (near) equivalence of cost-effectiveness and costbenefit analyses: Fact or fallacy?
23. Implantable cardioverter-defibrillator: A Volkswagen or a Rolls Royce: How much will we pay to save a life?
24. Clinical classification of cardiac deaths
25. The distinction between cost and charges